The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational post...

Full description

Bibliographic Details
Published in:International Journal of Circumpolar Health
Main Authors: G. G. Alvarez, D. Van Dyk, R. Mallick, S. Lesperance, P. Demaio, S. Finn, S. Edmunds Potvin, M. Patterson, C. Pease, K. Amaratunga, C. Hui, D.W. Cameron, S. Mulpuru, S.D. Aaron, F. Momoli, A. Zwerling
Format: Article in Journal/Newspaper
Language:English
Published: Taylor & Francis Group 2020
Subjects:
inuit
tuberculosis
latent tuberculosis infection treatment
Arctic medicine. Tropical medicine
RC955-962
Arctic
Nunavut
Canada
Qikiqtarjuaq
Circumpolar Health
International Journal of Circumpolar Health
Iqaluit
Online Access:https://doi.org/10.1080/22423982.2020.1758501
https://doaj.org/article/16425fe448d14bd6920642445f46808f

Similar Items